Antitubercular Bis-Substituted Cyclam Derivatives: StructureâActivity

Subscriber access provided by UNIV OF SCIENCES PHILADELPHIA

Anti-Tubercular bis-Substituted Cyclam Derivatives: Structure-Activity Relationships and In Vivo Studies Malcolm Spain, Joseph K.-H. Wong, Gayathri Nagalingam, James M. Batten, Elinor Hortle, Stefan Oehlers, Xiao Fan Jiang, Hasini E. Murage, Jack T. Orford, Patrick Crisologo, James A Triccas, Peter J. Rutledge, and Matthew H. Todd J. Med. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.jmedchem.7b01569 • Publication Date (Web): 20 Mar 2018 Downloaded from http://pubs.acs.org on March 21, 2018

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 64 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Journal of Medicinal Chemistry

Anti-Tubercular bis-Substituted Cyclam Derivatives: Structure-Activity Relationships and In Vivo Studies Malcolm Spain,† Joseph K.-H. Wong,† Gayathri Nagalingam,‡ James M. Batten,† Elinor Hortle,§ Stefan Oehlers,^ Xiao Fan Jiang,† Hasini E. Murage,† Jack T. Orford,† Patrick Crisologo,† James A. Triccas,‡ Peter J. Rutledge*,† and Matthew H. Todd.*,† † School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia ‡ Microbial Immunity and Pathogenesis Group, Department of Infectious Diseases and Immunology, Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia § Tuberculosis Research Program, Centenary Institute, Royal Prince Alfred Hospital, Missenden Road, Camperdown, Sydney, NSW 2050, Australia. ^ Central Clinical School, Sydney Medical School, The University of Sydney, Sydney, NSW 2006, Australia Tuberculosis,

mycobacteria,

structure

activity

relationship,

cyclam,

in

vivo

studies.

Abstract. We recently reported the discovery of non-toxic cyclam-derived compounds that are active against drug-resistant Mycobacterium tuberculosis. In this paper we report exploration of the structure-activity relationship for this class of compounds, identifying several simpler compounds with comparable activity. The most promising compound identified, possessing significantly improved water solubility, displayed high levels of bacterial clearance in an in vivo zebrafish embryo model, suggesting this compound series has promise for in vivo treatment of tuberculosis.

ACS Paragon Plus Environment

Journal of Medicinal Chemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

INTRODUCTION

Antimicrobial resistance represents a current worldwide threat to human health and an increasing burden upon healthcare.1-4 An estimated 1.7 billion people were infected with latent tuberculosis (TB) in 2014, leading to 10.4 million incident cases and 1.8 million deaths in 2015.5,6 In the treatment of tuberculosis, multi-drug therapy of first-line drugs are used over long periods of time (typically 6 months) to address the challenge of resistance.7 However, poor adherence to the long treatment regimens has been implicated in the rise of drug resistant TB strains.7,8 In 2015, 480,000 cases of multi-drug-resistant TB (MDR-TB) were reported, requiring longer and more expensive treatment programs.6,7 Furthermore, mismanagement of MDR-TB has led to extensively-drug-resistant TB (XDR-TB) being reported in 117 countries.7 The rise in drug-resistant forms of TB is a global public health crisis and requires the urgent development of new small molecule drugs.7,9,10 During M. tuberculosis infection in humans, host phagocytes take up bacteria, which can replicate within these cells; as the infection progresses, aggregation of further immune cells leads to granulomas where bacteria can remain for long periods of time.11 Commonly, TB results from re-activation of established granulomas in individuals infected with latent TB, with a 10% chance of activation over a lifetime.11 As such, granulomas represent an important and characteristic feature of TB infections. Recently, zebrafish (Danio rerio) infected with Mycobacterium marinum, a close relative of M. tuberculosis, have been used to study mycobacterial granulomas. The translucency of the zebrafish allows the infection, and hence the impact of treatment, to be observed over time. The zebrafish-M. marinum infection platform is


Page 2 of 64

Page 3 of 64 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


thus amenable for investigating the efficacy of novel antibiotic compounds within an in vivo infection context.12 We have shown the promising activity of cyclam-based ligands and their copper and zinc complexes against virulent and drug-resistant M. tuberculosis strains.13 These compounds are non-toxic and active against intracellular M. tuberculosis. Herein we present our progress in determining the structure-activity relationship (SAR) of the cyclam compound 1 (Figure 1), which possesses a cyclic cyclam core linked to two identical naphthalimide pendants via triazole linkers. RESULTS AND DISCUSSION

The SAR was determined through the symmetric modification of the two pendant groups of 1, the linker groups and investigations into the impact of metal complexation upon biological activity.

Figure 1. Most important hit compound 1 against M. tuberculosis (from our previous study see ref. 13), a bis-substituted cyclam core with pendant naphthalimide groups linked through 1,2,3triazoles. To investigate the pendant groups, compounds 5a-h were synthesized through coppercatalysed azide-alkyne cycloaddition (CuAAC) between bis-alkyne 2 and the corresponding azides 3a-h, to yield 4a-h followed by Boc deprotection (Scheme 1).



Scheme 1. Synthesis of compounds to investigate the pendant groups. Naphthalimides represent key structural features in a range bioactive compounds14 including anti-tumor, anti-viral and anti-bacterial compounds, while their fluorescent properties make them widely used probes.13,15 However, inclusion of the naphthalimide group can lead to compounds of low water solubility. In an attempt to lower molecular weight and increase water solubility relative to parent compound 1, a range of pendant groups was tested, maintaining the cyclam core and triazole linkers (Figure 2). Pleasingly replacing the naphthalimide in 1 (MIC 3.13 µM) with simple naphthalene-based pendant groups (5a-b) maintained some of the superior activity of the naphthalimide.16 However, single aromatic ring pendants 5c-h15c including a diversity of aromatic electron density, with or without a methylene spacer, exhibited low potency. Thus while the naphthalimide can be replaced by simpler 1-naphthyl groups, single aromatic rings were not found to be suitable replacements.


Page 4 of 64

Page 5 of 64 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Figure 2. Pendant group SAR. Potencies are MIC vs. H37Rv using concentration of compound as determined by the resazurin viability assay (see the experimental section for details). Due to the ease of synthesis and promising activity of simple naphthyl groups, the 1-naphthyl pendant group was maintained while other linking groups were investigated. Compound 9a was synthesized through CuAAC between bis-azide 6 and the corresponding alkyne 7a, to yield 8a followed by Boc deprotection (Scheme 2). To investigate the simple alkyl linker groups compound 13 was synthesized through alkylation of 10 with bromide 11 followed by hydrolysis and hydrogenation of intermediate 12 to yield 13 (Scheme 2).

Scheme 2. Synthesis of compounds to investigate the linker group.



Interestingly, the alkane linker in 13 maintained similar bioactivity (25–50 µM) versus the triazole-based compound 5a (Figure 3), suggesting that flexible and non-coordinating linker groups can maintain bioactivity. Importantly, introducing an extra methylene group and changing the 1,2,3-triazole connectivity to be C-linked to the pendant group in 9a resulted in a more potent compound (6.25 µM) suggesting that positioning of the pendants, as opposed to the flexibility of the linker, is a key determinant of potency.

Figure 3. Linker group SAR. Potencies are MIC vs. H37Rv Previous medicinal chemistry studies on the treatment of HIV with cyclam-derived compounds noted that the coordinating metal ion impacted on biological activity.17 Thus we investigated a variety of complexes of 1 (Table 1) using metal ions of different radii and ionic charge. Previously, we reported 14a-b,13 the Zn2+ and Cu2+ salts, which both had similar anti-tubercular activities to the free amine 1 and salt.13 Metal complexes of Fe2+ (14c, ionic radius 0.61 Å), Fe3+ (14d, 0.55 Å), Sm3+ (14e, 0.96 Å), Co2+ (14f, 0.65 Å) and Mn2+ (14g, 0.67 Å) were synthesized by complexation with 1 and evaluated showing no significant difference in anti-tubercular activity, strongly suggesting that the identity of the metal centre is not important. However it remains possible that metal ion exchange is occurring to give an active compound under the assay conditions.18 Additionally, the Zn2+ (15a) and Cu2+ (15b) complexes of the simpler naphthyl compound 5a were synthesized and also screened for anti-tubercular activity displaying increased activity relative to the corresponding metal-free compound.


Page 6 of 64

Page 7 of 64 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Table 1. Activity of metal complexes 14a-g and 15a-b.

Compound

a

Complexationa

Ionic

radius MIC

(Å)b

(µM)c

vs.

1d

n/a

n/a

3.13 – 6.25

14ad

1 + Zn(ClO4)2

0.74

3.13 – 6.25

14bd

1 + Cu(ClO4)2

0.73

6.25

14c

1 + Fe(ClO4)2

0.61

3.13

14d

1 + Fe(ClO4)3

0.55

3.13

14e

1 + Sm(ClO4)3

0.96

1.56 – 3.13

14f

1 + Co(ClO4)2

0.65

3.13 – 6.25

14g

1 + Mn(ClO4)2

0.67

3.13

5a

n/a

n/a

25 – 50

15a

5a + Zn(ClO4)2

0.74

3.13

15b

5a + Cu(ClO4)2

0.73

3.13

H37Rv

All compounds were complexed as detailed in the SI. bIonic radii based on the hexacoordinate

metals.19 cSee experimental section for details. dSee ref. 13 for details.



Having observed increased potency for the 1-naphthyl substituted compound 9a (Figure 3) which has the ‘reversed’ triazole connectivity relative to the parent compound 1 (and 5a), we investigated a range of pendant groups with this alternative triazole linker (Figure 4). Compounds 9b-e were synthesized through CuAAC between bis-azide 6 and the corresponding alkyne 7b-e, followed by Boc deprotection (Scheme 2). Interestingly, the obvious naphthalimidesubstituted compound 9b15c exhibited reduced activity (25 µM), but the 2-naphthyl pendant 9c (6.25 µM) displayed comparable activity to the original 1-naphthyl compound 9a. Surprisingly, the compound with simple phenyl pendant groups (9d)15c exhibited moderate activity, while benzyl groups (9e) were inactive. Additionally Zn2+ and Cu2+ complexes of these compounds (16a-20b) were synthesized and screened for activity (Table 2), with the results clearly suggesting Cu2+ complexation is beneficial for anti-tubercular activity in this series: for example, Cu2+ complex 20b regains high activity, from the inactive ligand 9e whilst the Zn2+ complex 20a does not.

Figure 4. Pendant group SAR with the alternative linker topology. Table 2. Activity of Zn2+ and Cu2+ metal complexes (16a-20b) of compounds 9a-e.


Page 8 of 64

Page 9 of 64 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Compound Complexationa

MIC vs. H37Rv (µM)b

9a

n/a

6.25

16a

9a + Zn(ClO4)2

6.25

16b

9a + Cu(ClO4)2

3.13

9bc

n/a

25

17ac

9b + Zn(ClO4)2

25

17bc

9b + Cu(ClO4)2

6.25

9c

n/a

6.25

18a

9c + Zn(ClO4)2

3.13

18b

9c + Cu(ClO4)2

3.13

9dc

n/a

50

19ac

9d + Zn(ClO4)2

50

19bc

9d + Cu(ClO4)2

6.25



a

9e

n/a

>100

20a

9e + Zn(ClO4)2

>100

20b

9e + Cu(ClO4)2

6.25

Free amines were complexed with the relevant metal perchlorate salts detailed in the SI. bSee

experimental section for details. cSee ref. 15c for synthetic details. The SAR suggests that napthalimides can be replaced by simple naphthyl substituents, and various linker groups and metal complexes can be tolerated without significant changes in activity. SAR around the optimal linker proved more complicated, and in some cases dependent on metal ion complexation, with distinct preference for the Cu2+-complex. The initial hit compound 1 exhibits a good combination of activity, synthetic simplicity, and importantly possibilities for further functionalization of the N-substituent of the naphthalimide. Therefore, modifications to increase solubility were sought by simple changes at this position, by incorporating 3-aminopropanol derived naphthalimides (Table 3). Although some of our results suggest a potential benefit of Cu2+-complexes, this was not observed in the related series 14a-g, therefore Zn2+-complexes were synthesized for their superior fluorescence properties. Previously, the kinetic solubility of the Zn(ClO4)2 complex of 1 had been studied,13 and correlates to the 97% from Sigma-Aldrich, contains approx. 17% of 2-(chloromethyl)naphthalene by 1H-NMR)) and NaN3 (0.745 g, 11.5 mmol, 1.8



Page 16 of 64

equiv.) in MeCN (10 mL, 0.6 M) were refluxed for 17 h. The reaction was carefully concentrated, diluted with H2O (10 mL) and extracted with diethyl ether (3 × 10 mL), the organic layers were dried over MgSO4 and carefully concentrated to yield 3b as a colourless oil (0.770 g, 4.2 mmol, 64%, contains 2-(azidomethyl)naphthalene) impurities that could not be separated by HPLC). 1H NMR (300 MHz, CDCl3): δ 4.71 (s, 2 H), 7.41 – 7.57 (m, 4 H), 7.81 – 7.87 (m, 2 H), 8.00 (d, J 8.0, 1 H). LRMS (ESI+): m/z Not found. 1H NMR matched those previously described.23 1-Azido-4-nitrobenzene (3d). Similar to the procedure for 3a, 4-nitroaniline (443 mg, 3.21 mmol, 1.0 equiv.), H2O (2 mL), conc. HCl (1 mL), NaNO2 (289 mg, 4.19 mmol, 1.3 equiv.) in H2O (1 mL), NaN3 (251 mg, 3.87 mmol, 1.2 equiv.) in H2O (1 mL) for 1 h extracted, dried over Na2SO4 and concentrated to yield 3d as a yellow solid (525 mg, 3.20 mmol, 99%). 1H NMR (300 MHz, CDCl3): δ 7.10 – 7.20 (m, 2 H), 8.24 – 8.30 (m, 2 H) 13C NMR (50 MHz, CDCl3): δ 119.4, 125.6, 144.7, 146.9. FTIR (ATR) νmax/cm-1: 2120, 2100, 1611. Spectroscopic properties matched those previously described.21 1-Azido-4-methoxybenzene (3e). Similar to the procedure for 3a, p-anisidine (396 mg, 3.21 mmol, 1.0 equiv.), H2O (2 mL), conc. HCl (1 mL), NaNO2 (289 mg, 4.19 mmol, 1.3 equiv.) in H2O (1 mL), NaN3 (251 mg, 3.87 mmol, 1.2 equiv.) in H2O (1 mL) for 1 h extracted, dried over Na2SO4 and concentrated to yield 3e as a dark brown solid (319 mg, 2.15 mmol, 67%). 1H NMR (300 MHz, CDCl3): δ 3.82 (s, 3 H), 6.90 – 6.94 (m, 2 H), 6.96 – 7.00 (m, 2 H)

13

C NMR (50

MHz, CDCl3): δ 55.6, 115.2, 120.0, 132.4, 157.1. FTIR (ATR) νmax/cm-1: 2108, 1602. Spectroscopic properties matched those previously described.21 Azidomethyl benzene (3f). Based on the literature procedure.24 To a solution of benzyl bromide (1 mL, 8.4 mmol, 1 equiv.) in acetone (1 mL) and H2O (1 mL) was added , NaN3 (1.9 g,


Page 17 of 64 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


30.2 mmol, 3.6 equiv.) the reaction mixture was stirred at rt for 2 h. The reaction was diluted with H2O (10 mL) and extracted with Et2O (3 × 10 mL) and dried over Na2SO4 and concentrated to yield 3f as a colourless oil (770 mg, 5.8 mmol, 69%). 1H NMR (300 MHz, CDCl3): δ 4.37 (s, 2 H), 7.32 – 7.45 (m, 5 H)

13

C NMR (50 MHz, CDCl3): δ 54.8, 128.3, 128.4, 128.9, 135.5.

FTIR (ATR) νmax/cm-1: 2089, 1605. Spectroscopic properties matched those previously described.25 1-(Azidomethyl)-4-nitrobenzene (3g). Similar to the procedure for 3f, 4-nitrobenzyl bromide (416 mg, 2 mmol, 1 equiv.), NaN3 (484 mg, 7.4 mmol, 3.7 equiv.), acetone:H2O (2 mL, 3:1) for 2 h. The reaction was diluted with H2O (10 mL) extracted with Et2O (3 × 20 mL) and dried over Na2SO4 and concentrated to yield 3g as a colourless oil (332 mg, 1.86 mmol, 93%). 1H NMR (300 MHz, CDCl3): δ 7.52 (d, J 9.0, 2 H), 8.21 (d, J 9.0, 2 H)

13

C NMR (50 MHz, CDCl3): δ

53.6, 123.8, 128.4, 142.6, 147.6. FTIR (ATR) νmax/cm-1: 2107, 1607. Spectroscopic properties matched those previously described.26 1-(Azidomethyl)-4-methoxybenzene (3h). Following a literature procedure,27 to a vial charged with 4-methoxybenzyl chloride (313 mg, 2.0 mmol, 1 equiv.) and NaN3 (484 mg, 7.4 mmol, 3.7 equiv.) was added THF (2 mL) and stirred at rt for 1 h. The reaction was diluted with H2O (10 mL) extracted with Et2O (3 × 20 mL), dried over Na2SO4 and concentrated to yield 3h as a colourless oil (280 mg,1.88 mmol, 94%). 1H NMR (300 MHz, CDCl3): δ 3.78 (s, 3 H), 4.23 (s, 2 H), 6.89 (d, J 8.5, 2 H), 7.22 (d, J 8.5, 2 H)

13

C NMR (50 MHz, CDCl3): δ 54.4, 55.3,

114.2, 127.4, 129.6, 156.6. FTIR (ATR) νmax/cm-1: 2096. Spectroscopic properties matched those previously described.27 6-Azido-2-(3-hydroxypropyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (3i). Following a literature 2-step procedure,15a to a suspension of 4-bromo-1,8-naphthalic anhydride (7.5 g, 27.1



mmol, 1 equiv.) in ethanol (0.54 M, 50 mL) was added 3-aminopropan-1-ol (2.1 mL, 27.1 mmol, 1.0 equiv.) and heated to reflux for overnight. The reaction was cooled to rt and filtered, collecting to yield the intermediate 6-bromo-2-(3-hydroxypropyl)-1H-benzo[de]isoquinoline1,3(2H)-dione as a light brown powder (8.6 g, 25.7 mmol, 95%). 1H NMR (300 MHz, CDCl3):

δ 2.00 (app. quin, J 6.0, 2 H), 2.96 (t, J 6.0, 1 H), 3.61 (app. q, J 6.0, 2 H), 4.36 (t, J 6.0, 2 H), 7.88 (dd, J 8.5, 7.0, 1 H), 8.07 (d, J 8.0, 1 H), 8.45 (d, J 8.0, 1 H), 8.61 (dd, J 8.5, 1.0, 1 H), 8.69 (dd, J 7.0, 1.0, 1 H). 13C NMR (75 MHz, CDCl3): δ 31.0, 37.0, 58.9, 121.7, 122.6, 128.1, 128.8, 130.5, 130.6, 131.1, 131.4, 132.2, 133.4, 164.1, 164.3. FTIR (ATR) νmax/cm-1: 1701, 1655. Spectroscopic properties matched those previously described.15a The intermediate was then converted to the azide product using a reaction carried out at a maximum of 3.0g scale for safety reasons. To 6-bromo-2-(3-hydroxypropyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (3.00 g, 9.0 mmol, 1.0 equiv.) in NMP (10 mL, 0.9 M) was added NaN3 (3.27 g, 50.2 mmol, 5.6 equiv.) was heated to 110 °C for 45 mins and cooled to rt. The reaction mixture was diluted with water (60 mL) and filtered collecting the precipitate which was dried under high vacuum to yield 3i as a brown solid (2.58 g, 0.87 mmol, 97%). 1H NMR (300 MHz, CDCl3): δ 1.85 – 1.97 (m, 2 H), 3.52 (t, J 5.5, 2 H), 4.26 (t, J 6.0, 2 H), 7.39 (d, J 8.0, 1 H), 7.67 (m, 1 H), 8.37 (d, J 8.5, 1 H), 8.50 (d, J 8.0, 1 H), 8.56 (d, J 7.0, 1 H). 13C NMR (75 MHz, CDCl3): δ 30.9, 36.8, 58.9, 114.7, 118.4, 122.2, 124.2, 124.3, 126.9, 129.0, 132.0, 132.5, 143.3, 162.3, 164.5. FTIR (ATR) νmax/cm-1: 2125, 1697, 1654, 1589. Spectroscopic properties matched those previously described.15a Di-tert-butyl

4,11-bis((1-(naphthalen-1-yl)-1H-1,2,3-triazol-4-yl)methyl)-1,4,8,11-

tetraazacyclotetradecane-1,8-dicarboxylate (4a). To a flask charged with N2 was added 3a (511 mg, 3.02 mmol, 2.4 equiv.) and 2 (591 mg, 1.25 mmol, 1 equiv.), then THF (13 mL) and


Page 18 of 64

Page 19 of 64 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


H2O (13 mL) (0.16 M of cyclam in the 1:1 mixture of THF:H2O) the reaction mixture was backfilled with N2 (× 5, fast), CuSO4·5H2O (63 mg, 20 mol%) and sodium ascorbate (110 mg, 50 mol%) were added and backfilled with N2 (× 3, fast) and the reaction mixture was stirred at rt for 20 h. The reaction mixture was concentrated to remove THF and diluted with aqueous saturated NH4Cl (20 mL) and extracted with DCM (3 × 50 mL). The combined organic layers were dried over Na2SO4 and concentrated by rotary evaporation to yield the crude product which was purified using automated flash chromatography 0–100% EtOAc-Petroleumn benzene over 10 CV, to yield 4a as a brown foamy solid (584 mg, 58%). m.p. 85 – 96 °C. 1H NMR (200 MHz, CDCl3): δ 1.34 – 1.40 (br. s, 18 H), 1.70 – 2.00 (m, 4 H), 2.60 (t, J 6.0, 4 H), 2.72 (t, J 6.0, 4 H), 3.24 – 3.61 (m, 8 H), 3.91 (s, 4 H), 7.39 – 7.67 (m, 12 H), 7.85 – 8.05 (m, 4 H). 13C NMR (75 MHz, CDCl3): δ 26.5, 28.4, 46.9, 50.1, 51.9, 53.6, 61.9, 79.3, 122.3, 124.7, 124.9, 126.9, 127.8, 128.2, 128.4, 130.1, 133.7, 134.0, 140.4, 155.7 (1 × quaternary aromatic signal not seen or overlapping) LRMS (ESI+): m/z 815.49 ([M+H]+, 100%). Di-tert-butyl

4,11-bis((1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1,4,8,11-

tetraazacyclotetradecane-1,8-dicarboxylate (4d). Similar to the procedure for 4a, 3d (0.84 mmol, 137.2 mg, 2.09 equiv.) and 2 (238 mg, 0.4 mmol, 1 equiv.) in THF (1.7 mL) and H2O (1.7 mL), CuSO4·5H2O (20 mg, 20 mol%) and sodium ascorbate (35 mg, 50 mol%) and stirred at rt for 1 h. The reaction mixture was concentrated and purified by flash chromatography (0 – 100% DCM-MeOH, over 5 CV to remove azide) then 100% MeOH (5 CV)) to yield 4d as an orange foamy solid (171 mg, 0.21 mmol, 53%). 1H NMR (500 MHz, CDCl3): δ 1.19 – 1.53 (m, 18 H), 1.76 – 1.86 (br. m, 4 H), 2.53 – 2.59 (br. m, 4 H), 2.60 – 2.71 (br. m, 4 H), 3.26 – 3.60 (m, 8 H), 3.86 (br. s., 4 H), 7.86 – 8.15 (m, 6 H), 8.26 – 8.47 (m, 4 H)

13

C NMR (126 MHz, CDCl3): δ

27.0, 28.4, 46.9, 47.5, 50.2, 52.2, 54.5, 79.5, 120.3, 120.7, 125.4, 141.1, 147.0, 147.2, 155.9.



LRMS (ESI+): m/z 805.46 ([M+H]+, 100%). HRMS (ESI+): m/z Calcd. for C38H53N12O8+ 805.4109, found 805.4109. Di-tert-butyl

4,11-bis((1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)-1,4,8,11-

tetraazacyclotetradecane-1,8-dicarboxylate (4e). Similar to the procedure to 4a, 3e (0.84 mmol, 125 mg, 2.09 equiv.) and 2 (238 mg, 0.4 mmol, 1 equiv.) in THF (1.7 mL) and H2O (1.7 mL) CuSO4·5H2O (20 mg, 20 mol%) and sodium ascorbate (35 mg, 50 mol%) and stirred at rt for 1 h. The reaction mixture was concentrated and purified by flash chromatography (0 – 100% DCM-MeOH, over 5 CV to remove excess 3e) and 100% MeOH (5 CV) to yield 4e as a yellowgreen solid (140 mg, 0.18 mmol, 45%). 1H NMR (500 MHz, CDCl3): δ 1.22 – 1.50 (br. s, 18 H), 1.82 – 1.86 (br. m, 4 H), 2.51 – 2.65 (br. m, 4 H), 2.63 – 2.71 (br. m, 4 H), 3.26 – 3.58 (m, 8 H), 3.81 – 3.86 (br. m, 10 H), 6.90 – 6.95 (br. m, 4 H), 7.56 – 7.62 (br. m, 4 H), 7.74 – 7.80 (br. s, 2 H)

13

C NMR (126 MHz, CDCl3): δ 26.9, 28.4, 46.8, 47.4, 50.0, 52.0, 55.5, 79.6, 114.6, 115.1,

121.9, 122.1, 130.1, 155.9, 159.6. LRMS (ESI+): m/z 775.51 ([M+H]+, 100%). HRMS (ESI+): m/z Calcd. for C40H59N10O6+ 775.4619 found 775.4620. Di-tert-butyl

4,11-bis((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-1,4,8,11-

tetraazacyclotetradecane-1,8-dicarboxylate (4f). Similar to the procedure for 4a, 3f (0.84 mmol, 160 mg, 2.09 equiv.) and 2 (238 mg, 0.4 mmol, 1 equiv.) in THF (1.7 mL) and H2O (1.7 mL) were added CuSO4·5H2O (20 mg, 20 mol%) and sodium ascorbate (35 mg, 50 mol%) and stirred at rt for 1 h. The reaction mixture was concentrated and purified by flash chromatography (0 – 15% DCM-MeOH, over 10 CV) to yield 4f as a white foamy solid (95 mg, 0.13 mmol, 32%). 1H NMR (500 MHz, CDCl3): δ 1.39 (br. s., 18 H), 1.62 – 1.76 (m, 4 H), 2.35 – 2.48 (m, 4 H), 2.49 – 2.64 (m, 4 H), 3.14 – 3.41 (m, 8 H), 3.62 – 3.81 (m, 4 H), 5.49 (d, J 14.5, 4 H), 7.24 (br. s., 4 H), 7.31 – 7.38 (br. m, 8 H)

13

C NMR (126 MHz, CDCl3): δ 26.5, 28.4, 46.4, 47.0,


Page 20 of 64

Page 21 of 64 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


50.4, 52.0, 53.6, 54.0, 79.2, 122.3, 127.9, 128.6, 129.0, 134.9, 145.0, 155.7. LRMS (ESI+): m/z 743.20 ([M+H]+, 100%). Di-tert-butyl

4,11-bis((1-(4-nitrobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1,4,8,11-

tetraazacyclotetradecane-1,8-dicarboxylate (4g). Similar to the procedure for 4a, 3g (0.84 mmol, 150 mg, 2.09 equiv.) and 2 (238 mg, 0.4 mmol, 1 equiv.) in THF (1.7 mL) and H2O (1.7 mL) and CuSO4·5H2O (20 mg, 20 mol%) and sodium ascorbate (35 mg, 50 mol%) for 1 h at rt. The reaction mixture was concentrated and purified by flash chromatography ((0 – 15% DCMMeOH, over 10 CV)) to yield 4g as a yellow foamy solid (120 mg, 0.14 mmol, 36%). 1H NMR (500 MHz, CDCl3): δ 1.40 (br. s., 18 H), 1.60 – 1.84 (br. m, 4 H), 2.36 – 2.50 (m, 4 H), 2.52 – 2.63 (m, 4 H), 3.18 – 3.48 (br. m, 8 H), 3.72 (br. s., 4 H), 5.64 (br. s., 4 H), 7.40 (d, J 8.5, 4 H), 7.45 – 7.65 (br. s., 2 H), 8.22 (d, J 8.5, 4 H)

13

C NMR (126 MHz, CDCl3): δ 26.7, 28.4, 46.6,

49.8, 50.5, 52.1, 53.0, 54.3, 79.4, 122.7, 124.3, 128.5, 142.0, 148.0, 155.7, 158.1. LRMS (ESI+): m/z 833.44 ([M+H]+, 100%). HRMS (ESI+): m/z Calcd. for C40H57N12O8+ 833.4422, found 833.4429. Di-tert-butyl

4,11-bis((1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1,4,8,11-

tetraazacyclotetradecane-1,8-dicarboxylate (4h). Similar to the procedure for 4a, 3h (0.84 mmol, 137 mg, 2.09 equiv.) and 2 (238 mg, 0.4 mmol, 1 equiv.) in THF (1.7 mL) and H2O (1.7 mL) and CuSO4·5H2O (20 mg, 20 mol%) and sodium ascorbate (35 mg, 50 mol%) for 1 h at rt. The reaction mixture was concentrated and purified by flash chromatography (0 – 15% DCMMeOH, over 10 CV) to yield 4h as a yellow foamy solid (155 mg, 0.19 mmol, 48%). 1H NMR (500 MHz, CDCl3): δ 1.34 – 1.43 (br. m, 18 H), 1.63 – 1.74 (br. m, 4 H), 2.38 – 2.46 (br. m, 4 H), 2.51 – 2.60 (br. m, 8 H), 3.15 – 3.40 (m, 8 H), 3.64 – 3.74 (br. m, 4 H), 3.78 (s, 6 H), 6.87 (d, J 8.5, 4 H), 7.14 – 7.25 (br. m, 4 H), 7.31 (br. s., 2 H)

13

C NMR (126 MHz, CDCl3): δ 27.1,



28.4, 46.5, 49.7, 50.4, 51.9, 53.6, 53.6 (HSQC), 55.3, 79.3, 114.4, 114.8, 122.1, 126.9, 129.6, 155.8, 159.8. HRMS (ESI+): m/z Calcd. for C42H63N10O6+ 803.4932, found 803.4934. Di-tert-butyl

4,11-bis((1-(2-(3-hydroxypropyl)-1,3-dioxo-2,3-dihydro-1H-

benzo[de]isoquinolin-6-yl)-1H-1,2,3-triazol-4-yl)methyl)-1,4,8,11-tetraazacyclotetradecane1,8-dicarboxylate (4i). To a flask charged with 3i (1.86 g, 6.29 mmol, 2.09 equiv.) and 2 (1.5 g, 3.15 mmol, 1 equiv.) was added THF (14 mL) and H2O (14 mL) (0.11 M of cyclam in the 1:1 mixture of THF:H2O) backfilled with N2 at this point (× 3). CuSO4·5H2O (157 mg, 20 mol% 0.63 mmol) and sodium ascorbate (0.281 g, 50 mol%, 1.6 mmol) were added and the reaction was backfilled with N2 (× 3). The reaction was stirred at rt (reached using a water bath at 25 oC) for 1 h. The reaction mixture was concentrated by rotary evaporation and purified by column chromatography (5% MeOH-DCM, to remove the 3i increasing to 40% MeOH-DCM). Fractions were combined which were >98% purity by HPLC (analytical run, 0 – 100% over 60 mins; MeCN-H2O (with 0.1% TFA) over 90 mins) to yield 4i as a yellow-brown solid (1.80 g, 1.68 mmol, 52%). 1H NMR (300 MHz, CDCl3): δ 1.34 – 1.43 (br. m, 22 H), 1.64 – 2.03 (br. m, 4 H), 2.55 – 2.59 (br. m, 4 H), 2.70 – 2.75 (br. m, 4 H), 3.20 – 3.42 (br. m, 8 H), 3.61 – 3.65 (br. m, 4 H), 3.91 – 4.02 (br. m, 4 H), 4.35 – 4.39 (br. m, 4 H), 7.85 – 7.92 (br. m, 4 H), 8.26 – 8.39 (br. m, 4 H), 8.72 – 8.70 (m, 4 H) 13C NMR (75 MHz, CDCl3): δ 28.4, 30.9, 37.2, 45.6, 47.5, 59.1, 79.7, 122.6, 123.4, 123.6, 125.1, 126.4, 128.7, 129.1, 130.0, 131.1, 132.4, 138.5, 155.7, 155.8, 163.2. FTIR (ATR) νmax/cm-1: 3055, 1662, 1647. Spectroscopic properties matched those previously described.15a 1,8-Bis((1-(naphthalen-1-yl)-1H-1,2,3-triazol-4-yl)methyl)-1,4,8,11tetraazacyclotetradecane (5a). To a solution of 4a (489 mg, 0.60 mmol) in 1,4-dioxane (3.0 mL, 0.2 M) was added HCl in dioxane (4.0 M, 4.8 mmol, 1.2 mL) and stirred at rt for 1 h. 1,4-


Page 22 of 64

Page 23 of 64 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


dioxane was removed by rotary evaporation to yield the salt of 5a·0.8 C4H8O2·3.8 H2O·3.4 HCl as pale brown powder (447 mg, 98%). m.p. 250 – 262 °C Anal.: Calculated for C36H42N10·0.8 C4H8O2·3.8 H2O·3.4 HCl: C 53.64 H 6.82 N 15.96; Found: C 53.64 H 6.77 N 15.96. Conversion of the salt (100 mg) to the amine was performed by reverse phase automated chromatography (0 – 100% MeCN-H2O (with 0.1% TFA) over 10 CV) and concentrated and extracted from 2.5 M aqueous NaOH (10 mL) with DCM (3 × 30 mL). The combined organic layers were dried over Na2SO4 and concentrated to yield 5a as a brown solid (35 mg, 0.057 mmol, 9.5% (43% based on the % purified), >95% purity by analytical HPLC). 1H NMR (300 MHz, CDCl3): δ 1.81 – 1.92 (br. s., 4 H), 2.55 – 2.62 (m, 4 H), 2.64 – 2.70 (br. m, 4 H), 2.71 – 2.81 (m, 8 H), 3.86 (s, 4 H), 7.45 – 7.60 (m, 10 H), 7.71 (s, 2 H), 7.83 – 7.91 (m, 2 H), 7.91 – 7.99 (m, 2 H) 13C NMR (75 MHz, CDCl3): δ 25.9, 47.3, 47.4, 49.9, 51.4, 54.2, 122.3, 123.5, 124.9, 125.2, 126.9, 127.7, 128.1, 128.5, 130.1, 133.7, 134.0, 143.2. LRMS (ESI+): m/z 615.38 ([M+H]+, 100%). HRMS (ESI+): m/z Cald. for C36H43N10 615.3672 found 615.3666. Anal.: Calculated for C36H42N10·0.8 C4H8O2·3.8 H2O·3.4 HCl: C 53.64 H 6.82 N 15.96; Found: C 53.64 H 6.77 N 15.96. 1,8-Bis((1-(naphthalen-1-ylmethyl)-1H-1,2,3-triazol-4-yl)methyl)-1,4,8,11tetraazacyclotetradecane (5b). Similar to the procedure for 4a, 3b (112 mg, 0.61 mmol, 2.4 equiv., contained 2-(azidomethyl)naphthalene as a minor impurity), 2 (123mg, 0.26 mmol, 1 equiv.), CuSO4·5H2O (7 mg, 10 mol%) and sodium ascobate (9 mg, 20 mol%) were reacted for 6 h at 50 ºC and concentrated by rotary evaporation. Saturated NH4Cl (50 mL) was added and extracted with DCM (3 × 50 mL) and dried over MgSO4 and concentrated to yield 4b as a crude mixture (crude yield 148 mg, 0.24 mmol, 92%). 1H NMR (300 MHz, CDCl3): δ 1.32 – 1.43 (br. s, 18 H), 1.46 – 1.60 (br. m, 4 H), 1.61 – 1.77 (br. m, 4 H), 2.24 – 2.38 (br. m, 4 H), 2.38 – 2.51 (br. m, 4 H), 2.95 – 3.27 (br. m, 8 H), 3.49 – 3.69 (br. s., 4 H), 5.75 – 6.03 (br. m, 2 H) 7.34 –



Page 24 of 64

7.54 (br. m, 10 H), 7.84 (d, J 8.0, 4 H), 7.94 (br. s., 2 H) LRMS (ESI+): m/z 843.50 [M+H]+, m/z 865.44 [M+Na]+. The crude products of 4b (148 mg) were dissolved in 1,4-dioxane (4 mL) and HCl in dioxane (16 equiv., 4.0 M) was added and stirred at rt for 16 h. The reaction mixture was concentrated and 16 mg of this mixture was purified by preparative RP-HPLC (gradient 20% to 40% MeCN in H2O (with 0.1% TFA), over 90 min) to yield 5b·3.6TFA·0.5H2O as a white solid (4 mg, 0.004 mmol, 3%). 1H NMR (300 MHz, D2O): δ 1.92 (br. m, 4 H), 2.66 (br. m, 4 H), 2.94 (br. m, 8 H), 3.23 (br. m, 4 H), 3.52 – 5.64 (br. s, 4 H), 5.90 – 6.02 (br. s, 4 H), 7.35 – 7.52 (br. s, 2 H), 7.53 – 7.65 (br. m, 2 H), 7.65 – 7.81 (br. m, 6 H), 8.05 – 8.19 (br. m, 6 H). 5b·3.6TFA·0.5H2O (5 mg) was converted to the amine (5b) for

13

C NMR analysis (by

extracting the compound with DCM (3 × 3 mL) from 2.5 M aqueous NaOH (5 mL). 1H NMR (500 MHz, CDCl3): δ 1.64 – 1.76 (m, 4 H), 2.38 (apparent t, J 5.5, 4 H), 2.48 – 2.53 (m, 4 H), 2.53 – 2.59 (m, 8 H), 3.61 (s, 4 H), 5.61 (s, 4 H), 7.29 (dd, J 8.5, 2.0, 2 H), 7.36 (br. s., 2 H), 7.44 – 7.50 (m, 4 H), 7.69 (s, 2 H), 7.74 – 7.81 (m, 6 H). 13C NMR (126 MHz, CDCl3): δ 25.5, 47.1, 48.1, 49.3, 51.7, 53.2, 54.1, 122.6, 125.2, 126.6, 126.7, 127.3, 127.7, 127.9, 129.1, 132.2, 133.1, 133.2, 144.4. LRMS (ESI+): m/z 643.37 ([M (free amine) +H]+, 100%). HRMS (ESI+): m/z calculated for C38H47N10 643.3956, found 643.3985 [M+H]+. Anal.: Calculated for C38H46N10·3.6CF3CO2H·0.5H2O: C 51.10 H 4.80 N 13.18; Found: C 51.29 H 4.88 N 13.10. 1,8-Bis((1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)methyl)-1,4,8,11-tetraazacyclotetradecane (5d). To 4d (80 mg, 0.1 mmol, 1 equiv.) in 1,4-dioxane (1 mL) was added HCl in dioxane (0.25 mL, 4.0 M, 8 equiv.) and the reaction mixture stirred at rt for 30 mins (typically precipitation occurs after 5 mins, the reactions can be followed by TLC an aliquot containing solid was added to a vial containing NaHCO3 (sat., 0.5 mL) and EtOAc (0.5 mL) the amine products have an RF of 0.00 in EtOAc, 10% MeOH-DCM and 1% NH4OH (aq.) in 10% MeOH-DCM). The reaction


Page 25 of 64 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


mixture was concentrated by rotary evaporation and purified by reverse-phase automated chromatography (0 – 100% MeCN-H2O (with 0.1% TFA) over 10 CV) the fractions were concentrated by rotary evaporation (to remove MeCN) and aqueous NaOH (5 mL, 2.5 M) was added and extracted with DCM (1 × 5 mL). The extracts were dried over Na2SO4 and concentrated to yield 5d as an orange solid (38 mg, 0.63 mmol, 63%, >98% purity by analytical HPLC). 1H NMR (500 MHz, CDCl3): δ 1.87 – 1.95 (m, 4 H), 2.58 – 2.63 (m, 4 H), 2.78 – 2.84 (m, 4 H) 2.84 – 2.96 (m, 8 H), 3.80 (s, 4 H), 8.09 (d, J 9.0, 4 H), 8.36 (d, J 9.0, 4 H), 8.64 (br. s., 2 H)

13

C NMR (126 MHz, CDCl3): δ 24.8, 47.1, 48.5, 50.5, 51.8, 53.4, 120.3, 121.6, 125.4,

141.1, 145.8, 147.0. LRMS (ESI+): m/z 605.29 ([M+H]+, 100%). HRMS (ESI+): m/z Calcd. for C28H37N12O4+ 605.3061, found 605.3060. FTIR (ATR) νmax/cm-1: 2963, 2823, 1598, 1523. 1,8-Bis((1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl)-1,4,8,11tetraazacyclotetradecane (5e). Similar to the procedure for 5d, 4e (78 mg, 0.1 mmol, 1 equiv.) in 1,4-dioxane (1 mL) and HCl in dioxane (4.0 M, 10 equiv., 0.25 mL) for 30 mins at rt. The reaction mixture was concentrated and purified by reverse phase by automated reverse phase column chromatography ((0 – 100%) MeCN-H2O (with 0.1% TFA) over 10 CV). After concentration of the fractions and freeze-drying the products were made into the free-amine by addition of 2.5 M NaOH (5 mL) and extracted with DCM (5 mL). The organic layer was dried over Na2SO4 and concentrated to yield 5e as a yellow solid (30 mg, 0.052 mmol, 52%, >98% purity by analytical HPLC). 1H NMR (500 MHz, CDCl3): δ 1.81 – 1.92 (m, 4 H), 2.59 (t, J 5.5, 4 H), 2.75 – 2.84 (m, 8 H), 2.85 – 2.95 (m, 4 H), 3.74 (s, 4 H), 3.82 (s, 6 H), 6.91 – 7.04 (m, 4 H), 7.59 – 7.69 (m, 4 H), 8.05 (s, 2 H) 13C NMR (126 MHz, CDCl3): δ 24.8, 47.0, 48.4, 48.5, 50.9, 51.7, 55.5, 114.7, 121.2, 121.8, 130.4, 144.6, 159.6. LRMS (ESI+): m/z 575.35 ([M+H]+,



Page 26 of 64

100%). HRMS (ESI+): m/z Calcd. for C30H43N10O2+ 575.3571, found 575.3568. FTIR (ATR) νmax/cm-1: 2948, 2823, 1685, 1513. 1,8-Bis((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-1,4,8,11-tetraazacyclotetradecane

(5f).

Similar to the procedure for 5d, 4f (74 mg, 0.1 mmol, 1 equiv.) in 1,4-dioxane (1 mL) was added HCl in dioxane (4.0 M, 10 equiv., 0.25 mL) for 30 mins at rt. The reaction mixture was concentrated and purified by automated reverse phase column chromatography ((0 – 100%) MeCN-H2O (with 0.1% TFA) over 10 CV). After concentration of the fractions and freezedrying the products were made into the free-amine by addition of 2.5 M NaOH (5 mL) and extracted with DCM (5 mL). The organic layer was dried over Na2SO4 and concentrated to yield 5f as a yellow solid (31 mg, 0.041 mmol, 41%, >98% purity by analytical HPLC). 1H NMR (500 MHz, CDCl3): δ 1.75 – 1.84 (br. m, 4 H), 2.44 – 2.54 (br. m, 4 H), 2.62 – 2.78 (br. m, 8 H), 2.75 – 2.84 (br. m, 4 H), 3.63 (s, 4 H), 5.45 (s, 4 H), 7.19 – 7.27 (m, 4 H), 7.27 – 7.34 (m, 6 H), 7.62 (s, 2 H)

13

C NMR (126 MHz, CDCl3): δ 24.6, 29.7, 46.8, 48.7, 51.4, 51.8, 54.0, 123.0, 128.1,

128.7, 129.0, 134.9, 144.6 LRMS (ESI+): m/z 543.35 ([M+H]+, 100%). HRMS (ESI+): m/z Calcd. for C30H43N10+ 543.3672, found 543.3669. FTIR (ATR) νmax/cm-1: 2935, 2815, 1459. 1,8-Bis((1-(4-nitrobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1,4,8,11-tetraazacyclotetradecane (5g). Similar to the procedure for 5d, 4g (83 mg, 0.1 mmol, 1 equiv.) in 1,4-dioxane (1 mL) and HCl in dioxane (4.0 M, 10 equiv., 0.25 mL) for 30 mins at rt. The reaction mixture was concentrated and purified by reverse phase by automated reverse phase column chromatography ((0 – 100%) MeCN-H2O (with 0.1% TFA) over 10 CV). After concentration of the fractions and freeze-drying the products were made into the free-amine by addition of 2.5 M NaOH (5 mL) and extracted with DCM (5 mL). The organic layer was dried over Na2SO4 and concentrated to yield 5g as a yellow solid (37 mg, 0.058 mmol, 58%, >98% purity by analytical HPLC). 1H


Page 27 of 64 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


NMR (500 MHz, CDCl3): δ 1.76 – 1.85 (m, 4 H), 2.46 – 2.55 (m, 4 H), 2.65 – 2.76 (m, 8 H), 2.78 – 2.85 (m, 4 H), 3.68 (s, 4 H), 5.65 (s, 4 H), 7.46 (d, J 8.5, 4 H), 7.83 (s, 2 H), 8.16 (d, J 8.5, 4 H) 13C NMR (126 MHz, CDCl3): δ 24.7, 47.0, 48.4, 48.8, 51.2, 51.7, 52.9, 123.5, 124.1, 128.8, 141.9, 144.6, 147.9. LRMS (ESI+): m/z 633.31 ([M+H]+, 100%). HRMS (ESI+): m/z Calcd. for C30H41N12O4+ 633.3374, found 633.3372. FTIR (ATR) νmax/cm-1: 2959, 2829, 1678, 1519. 1,8-Bis((1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1,4,8,11tetraazacyclotetradecane (5h). Similar to the procedure for 5d, 4h (80 mg, 0.1 mmol, 1 equiv.) in 1,4-dioxane (1 mL) and HCl in dioxane (4.0 M, 10 equiv., 0.25 mL) for 30 mins at rt. The reaction mixture was concentrated and purified by reverse phase by automated reverse phase column chromatography ((0 – 100%) MeCN-H2O (with 0.1% TFA) over 10 CV). After concentration of the fractions and freeze-drying the products were made into the free-amine by addition of 2.5 M NaOH (5 mL) and extracted with DCM (5 mL). The organic layer was dried over Na2SO4 and concentrated to yield 5h as a yellow solid (37 mg, 0.061 mmol, 61%, >98% purity by analytical HPLC). 1H NMR (500 MHz, CDCl3): δ 1.70 – 1.79 (br. m, 4 H), 2.41 – 2.50 (m, 4 H), 2.56 – 2.69 (m, 8 H), 2.71 – 2.78 (m, 4 H), 3.62 (s, 4 H), 3.76 (s, 6 H), 5.38 (s, 4 H), 6.83 (d, J 8.5, 4 H), 7.18 (d, J 8.5, 4 H), 7.47 (s, 2 H) 13C NMR (126 MHz, CDCl3): δ 24.8, 46.8, 48.4, 48.7, 51.5, 51.9, 53.5, 55.2, 114.3, 122.5, 126.7, 129.5, 144.3, 159.8. LRMS (ESI+): m/z 603.36 ([M+H]+, 100%). HRMS (ESI+): m/z Calcd. for C32H47N10O2+ 603.3884, found 603.3881. FTIR (ATR) νmax/cm-1: 2948, 2839, 1688, 1610. 6,6'-(((1,4,8,11-Tetraazacyclotetradecane-1,8-diyl)bis(methylene))bis(1H-1,2,3-triazole4,1-diyl))bis(2-(3-hydroxypropyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione) (5i). 4i (500 mg, 0.47 mmol, 1 equiv.) was dissolved in 1,4-dioxane (6 mL, 0.08M) and HCl in dioxane (4.0 M, 0.94 mL, 3.74 mmol, 8 equiv.) was added (instantaneous change giving a yellow-white



precipitate upon addition of HCl). The reaction mixture was left to stir at rt for 2 h and concentrated by rotary evaporation. The residue was dissolved in a mixture of EtOH (200 mL) and CHCl3 (200 mL) and Ambersep® 900 resin (hydroxide form, 200 mg, washed with MeOH (3 × 10 mL)) was added and the reaction stirred for 1 h at rt. The resin was removed by filtration (without washing the resin) and the filtrate concentrated by rotary evaporation to yield 5i as a light yellow powder (348 mg, 0.40 mmol, 85%). 1H NMR (300 MHz, D2O): δ 1.78 – 1.97 (m, 4 H), 2.08 – 2.22 (m, 4 H), 2.82 – 3.00 (m, 4 H), 3.03 – 3.17 (m, 4 H), 3.40 – 3.51 (m, 4 H), 3.53 – 3.63 (very br. m, 4 H), 3.64 – 3.72 (m, 4 H), 3.94 – 4.03 (m, 4 H), 4.06 – 4.15 (m, 4 H), 7.20 – 7.33 (m, 2 H), 7.56 – 7.71 (m, 4 H), 8.06 – 8.13 (m, 2 H), 8.21 – 8.27 (m, 2 H), 8.29 – 8.33 (m, 2 H) 1H NMR (300 MHz, CDCl3 (10% MeOD-d4)): δ 1.54 – 1.77 (m, 8 H), 2.31 – 2.63 (m, 16 H), 3.05 (br. s., 2 H), 3.39 (t, J 6.0, 4 H), 3.61 – 3.78 (br. m, 4 H), 4.00 (t, J 7.0, 4 H), 7.49 – 7.65 (m, 4 H), 7.93 (d, J 8.5, 2 H), 7.99 (s, 2 H), 8.35 (d, J 7.5, 4 H) 13C NMR (75 MHz, CDCl3 (10% MeOD-d4)): δ 24.7, 30.3, 37.3, 46.5, 49.8, 52.3, 53.3, 54.6, 59.1, 122.1, 123.1, 123.3, 125.6, 125.9, 128.1, 128.5, 129.2, 130.3, 131.7, 137.8, 143.2, 163.0, 163.6. HRMS (ESI+): m/z Calcd. for C46H53N12O6+ [M+H]+ 869.4211, found 869.4188. 1-Ethynylnaphthalene (7a). To a solution of 1-bromonaphthalene (285 mg, 1.38 mmol) in diisopropylamine (10 mL) was added Pd(PPh3)2Cl2 (48 mg, 68 µmol, 5mol%) and CuI (13 mg, 68 µmol, 5 mol%) under N2. Trimethylsilylacetylene (292 µL, 2.07 mmol) was added dropwise and the reaction mixture was stirred for 16 h at 80 ºC. The reaction mixture was filtered and concentrated by rotary evaporation. The residue was dissolved in CHCl3 (25 mL), washed with H2O (2 × 25 mL), dried over Na2SO4 and concentrated by rotary evaporation. The residue was purified by flash column chromatography (petroleum benzine) to yield the TMS-protected intermediate as a yellow oil (259 mg, 84%). 1H NMR (400 MHz, CDCl3): δ 0.33 (s, 9 H), 7.40


Page 28 of 64

Page 29 of 64 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


(dd, J 8.0, 7.0, 1 H), 7.51 (ddd, J 8.0, 7.0, 1.5, 1 H), 7.57 (ddd, J 8.5, 7.0, 1.5, 1 H), 7.70 (dd, J 7.0, 1.0, 1 H), 7.79 – 7.86 (m, 2 H), 8.31 – 8.36 (m, 1 H). LRMS (EI): m/z 209.2 ([M-CH3]+, 100%), 224.1 (M+, 58%). Spectroscopic properties matched those previously described.28 To a solution of the TMS-protected intermediate (255 mg, 1.14 mmol) in MeOH (10 mL) was added a solution of KOH (77 mg, 1.4 mmol) in H2O (2 mL). The reaction mixture was stirred for 16 h at rt. The volatiles were removed and H2O (25 mL) was added. The product was extracted with Et2O (2 × 25 mL), and the extracts were combined, washed with H2O (25 mL), dried over Na2SO4 and the solvent was removed by rotary evaporation. The residue was purified by flash column chromatography (petroleum benzine) to yield 7a as an orange oil (143 mg, 83%). 1H NMR (400 MHz, CDCl3): δ 3.47 (s, 1 H), 7.42 (dd, J 8.0, 7.0, 1 H), 7.49 – 7.55 (m, 1 H), 7.55 – 7.61 (m, 1 H), 7.74 (d, J 7.0, 1 H), 7.85 (d, J 8.0, 2 H), 7.36 (d, J 8.5, 1 H). LRMS (EI): m/z 152.2 (M+, 100%). Spectroscopic properties matched those previously described.29 2-Ethynylnaphthalene (7c). To a solution of 2-bromonaphthalene (500 mg, 2.42 mmol) in diisopropylamine (10 mL) was added Pd(PPh3)2Cl2 (102 mg, 6 mol%) and CuI (28 mg, 6 mol%) under N2. Trimethylsilylacetylene (512 µL, 3.62 mmol) was added dropwise and the reaction mixture was stirred for 16 h at 80 ºC. The reaction mixture was filtered and the solvent was removed by rotary evaporation. The residue was dissolved in DCM (50 mL), washed with H2O (2 × 25 mL), dried over Na2SO4 and concentrated by rotary evaporation. The residue was purified by automated flash column chromatography (100% petroleum benzine for 12 CV) to yield the TMS-protected intermediate as a brown oil (460 mg, 85%). 1H NMR (400 MHz, CDCl3): δ 0.28 (s, 9 H), 7.43 – 7.53 (m, 3 H), 7.72 – 7.83 (m, 3 H), 8.00 (s, 1 H). LRMS (EI): m/z 209.1 ([M-CH3]+, 100%), 224.0 (M+, 38%). Spectroscopic properties matched those previously described.30 To a solution of the TMS-protected intermediate (443 mg, 1.97 mmol) in



MeOH (10 mL) was added a solution of KOH (133 mg, 2.37 mmol) in H2O (2 mL). The reaction mixture was stirred at for 16 h at rt. The volatiles were removed and H2O (25 mL) was added. The product was extracted with Et2O (2 × 25 mL), and the extracts were combined, dried over Na2SO4 and the solvent was removed by rotary evaporation. The residue was purified by flash column chromatography (petroleum benzine) to yield 7c as a colourless oil (204 mg, 68%). 1H NMR (400 MHz, CDCl3): δ 3.14 (s, 1 H), 7.46 – 7.56 (m, 3 H), 7.75 – 7.86 (m, 3 H), 8.03 (br. s, 1 H). LRMS (EI): m/z 152.1 ([M]+, 100%). Spectroscopic properties matched those previously described.30 Di-tert-butyl

4,11-bis(2-(4-(naphthalen-1-yl)-1H-1,2,3-triazol-1-yl)ethyl)-1,4,8,11-

tetraazacyclotetradecane-1,8-dicarboxylate (8a). To 6 (102 mg, 0.189 mmol, 1 equiv.) and 7a (69 mg, 0.45 mmol, 2.4 equiv.) in THF (7 mL) were added an orange cloudy mixture of CuSO4·5H2O (5 mg, 10 mol%) and sodium ascorbate (6 mg, 20 mol%) in H2O (3 mL) was added (NOTE: ideally this should not be cloudy, but result in an oxygen sensitive clear brown solution if mixed under an inert atmosphere – our preferred procedure is to add the CuSO4·5H2O and sodium ascorbate as solids to degassed solvents or to the backfilled reaction flask containing solvents). The reaction mixture was stirred under N2 for 16 h at 50 °C. The reaction was quenched with saturated aqueous NH4Cl (25 mL), THF removed by rotary evaporation and extracted with EtOAc (2 × 25 mL). The combined organic extracts were dried over Na2SO4 and concentrated by rotary evaporation. The residue was purified by flash column chromatography (EtOAc:petroleum benzine = 1:1 to 3:2 to EtOAc) to yield 8a as a yellowish oil (112 mg, 70%). 1

H NMR (500 MHz, CDCl3): δ 1.44 (s, 18 H), 1.49 – 1.58 (m, 4 H), 2.37 (t, J 6.5, 4 H), 2.55 (t, J

5.5, 4 H), 2.86 (t, J 6.5, 4 H), 3.14 (t, J 5.0, 4 H), 3.21 (t, J 7.0, 4 H), 4.30 (t, J 5.0, 4 H), 7.41 – 7.52 (m, 6 H), 7.66 – 7.75 (m, 4 H), 7.77 – 7.86 (m, 4 H), 8.43 (d, J 8.0, 4 H). 13C NMR (125


Page 30 of 64

Page 31 of 64 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


MHz, CDCl3): δ 26.8, 28.4, 46.6, 46.8, 48.3, 52.4, 53.8, 55.1, 79.6, 123.3, 125.2, 125.5, 125.9, 126.5, 126.9, 128.0, 128.3, 128.7, 130.9, 133.8, 146.5, 155.7. LRMS (ESI+): m/z 843.3 ([M+H]+, 100%), 865.4 ([M+Na]+, 22%). HRMS (ESI+): m/z Calcd. for C48H63N10O4+ [M+H]+ 843.5028, found 843.5038. FTIR (ATR) νmax/cm-1: 2975, 2933, 1673, 1455, 1416, 1393, 1366, 1250, 1159, 1049, 910, 801, 777, 730, 646. Di-tert-butyl

4,11-bis(2-(4-(naphthalen-2-yl)-1H-1,2,3-triazol-1-yl)ethyl)-1,4,8,11-

tetraazacyclotetradecane-1,8-dicarboxylate (8c). Similar to the procedure for 8a, 7c (180 mg, 0.33 mmol, 1 equiv.) and 6 (122 mg, 0.80 mmol, 2.4 equiv.) in THF (7 mL), CuSO4·5H2O (9 mg, 10 mol%) and sodium ascorbate (11 mg, 20 mol%) in H2O (3 mL) for 16 h at 50 °C. The reaction was quenched with saturated aqueous NH4Cl (25 mL), THF removed by rotary evaporation and extracted with EtOAc (2 × 25 mL). The combined organic extracts were dried over Na2SO4 and concentrated by rotary evaporation and the residue purified by automated column chromatography (15% EtOAc in petroleum benzine over 1 CV, 15 to 100% over 10 CV, 100% over 1 CV) to yield 8c as an off-white gum (191 mg, 68%). 1H NMR (400 MHz, CDCl3): δ 1.37 – 1.51 (m, 4 H), 1.47 (s, 18 H), 2.29 (t, J 6.0, 4 H), 2.45 – 2.58 (m, 4 H), 2.69 – 2.81 (m, 4 H), 2.98 – 3.10 (m, 4 H), 3.10 – 3.24 (m, 4 H), 4.00 – 4.17 (m, 4 H), 7.40 – 7.51 (m, 4 H), 7.71 (s, 2 H), 7.77 – 7.84 (m, 2 H), 7.84 – 7.93 (m, 4 H), 7.93 – 8.01 (m, 2 H), 8.40 (s, 2 H).

13

C

NMR (100 MHz, CDCl3): δ 26.7, 28.6, 46.4, 47.2, 48.5, 52.6, 54.2, 55.4, 79.7, 121.4, 123.8, 124.2, 126.1, 126.5, 127.8, 128.1, 128.2, 128.6, 133.1, 133.6, 147, 155.9. LRMS (ESI+): m/z 843.2 ([M+H]+, 29%), 865.1 ([M+Na]+, 100%). HRMS (ESI+): m/z Calcd. for C48H63N10O4+ [M+H]+ 843.5028, found 843.5021. FTIR (ATR) νmax/cm-1: 2973, 1682, 1457, 1415, 1366, 1246, 1159, 1050, 908, 861, 820, 731, 476.



Di-tert-butyl

4,11-bis(2-(4-benzyl-1H-1,2,3-triazol-1-yl)ethyl)-1,4,8,11-

tetraazacyclotetradecane-1,8-dicarboxylate (8e). Similar to the procedure for 8a, 6 (172 mg, 0.32 mmol, 1 equiv.) and 3-phenyl-1-propyne (7e) (95 µL, 0.76 mmol, 2.4 equiv.) in THF (7 mL), CuSO4·5H2O (8 mg, 10 mol%) and sodium ascorbate (11 mg, 20 mol%) in H2O (3 mL) for 16 h at 50 °C. The reaction was quenched with saturated aqueous NH4Cl (25 mL), THF removed by rotary evaporation and extracted with EtOAc (2 × 25 mL). The combined organic extracts were dried over Na2SO4 and concentrated by rotary evaporation and the residue purified by flash column chromatography (EtOAc:petroleum benzine = 1:1 to EtOAc to MeOH: EtOAc 1:9) to yield 8e as an off-white gum (147 mg, 60%). 1H NMR (300 MHz, CDCl3): δ 1.44 (s, 18 H), 1.45 – 1.57 (m, 4 H), 2.38 (t, J 6.5, 4 H), 2.53 (t, J 5.5, 4 H), 2.85 (t, J 6.5, 4 H), 3.01 – 3.19 (m, 8 H), 4.06 (s, 4 H), 4.26 (t, J 6.5, 4 H), 7.15 – 7.34 (m, 12 H)

13

C NMR (75 MHz, CDCl3): δ 28.5,

32.2, 46.6, 46.8, 48.3, 52.5, 53.5, 55.3, 73.9, 79.5, 122.0, 126.4, 128.5, 128.7, 139.1, 147.3, 155.6. LRMS (ESI+): m/z 771.2 ([M+H]+, 100%), 793.1 ([M+Na]+, 45%). HRMS (ESI+): m/z Calcd. for C42H63N10O4+ [M+H]+ 771.5028, found 771.5035. FTIR (ATR) νmax/cm-1: 2974, 1678, 1494, 1454, 1413, 1391, 1365, 1248, 1154, 1074, 1048, 911, 774, 726, 698, 646, 463. 1,8-Bis(2-(4-(naphthalen-1-yl)-1H-1,2,3-triazol-1-yl)ethyl)-1,4,8,11tetraazacyclotetradecane (9a). To 8a (44 mg, 0.052 mmol) in 1,4-dioxane (2 mL) was added HCl in dioxane (4.0 M, 0.10 mL, 8 equiv.) and stirred for 16 h at rt. The residue was concentrated under reduced pressure and washed with EtOAc to yield 9a·3(HCl)·3H2O as a beige solid (37 mg, 94%). m.p.: 240 ºC (decomp.). 1H NMR (400 MHz, DMSO-d6): δ 1.81 – 1.93 (m, 4 H), 2.62 – 2.73 (m, 4 H), 2.80 – 2.92 (m, 4 H), 3.01 – 3.10 (m, 4 H), 3.13 (t, J 6.5, 4 H), 3.15 – 3.22 (m, 4 H), 4.65 (t, J 6.5, 4 H), 7.48 – 7.61 (m, 6 H), 7.74 (dd, J 7.0, 1.0, 2 H), 7.92 – 8.03 (m, 4 H), 8.44 – 8.51 (m, 2 H), 8.71 (s, 2 H), 8.74 (br. s, 2 H, NH) 13C NMR (100 MHz,


Page 32 of 64

Page 33 of 64 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


DMSO-d6): δ 22.7, 43.3, 44.6, 45.4, 48.6, 50.0, 50.4, 124.5, 125.2, 125.5, 126.0, 126.6, 126.7, 127.8, 128.5, 128.5, 130.1, 133.5, 145.6. LRMS (ESI+): m/z 643.3 (free base [M+H]+, 100%). HRMS (ESI+): m/z Calcd. for C38H47N10+ 643.3980, found 643.3984. FTIR (ATR) νmax/cm-1: 3396, 2956, 2615, 2418, 1653, 1586, 1453, 1393, 1354, 1259, 1220, 1049, 1018, 946, 800, 776, 743. Anal.: Calcd. for C38H46N10·3HCl·3H2O C 56.61, H 6.88, N 17.37; found C 56.44, H 6.76, N 17.20. 1,8-Bis(2-(4-(naphthalen-2-yl)-1H-1,2,3-triazol-1-yl)ethyl)-1,4,8,11tetraazacyclotetradecane (9c). 8c (59 mg, 0.070 mmol) was dissolved in a mixture of TFA (4 mL), H2O (0.5 mL) and CH2Cl2 (0.5 mL) and stirred for 4 h at rt. The reaction mixture was concentrated by rotary evaporation, and the residue triturated with EtOAc and purified by HPLC (0% to 100% MeCN in H2O (with 0.1% TFA) over 20 min) to yield 9c·2.5(TFA) as a white solid (42 mg, 68%). m.p.: 213 ºC (decomp.). 1H NMR (400 MHz, DMSO-d6): δ 1.67 – 1.78 (m, 4 H), 2.57 – 2.66 (m, 4 H), 2.67 – 2.75 (m, 4 H), 2.82 – 2.92 (m, 4 H), 3.02 (t, J 6.5, 4 H), 3.07 – 3.16 (m, 4 H), 4.59 (t, J 6.5, 4 H), 7.48 – 7.57 (m, 4 H), 7.88 – 8.02 (m, 8 H), 8.15 (br. s, 4 H, NH), 8.37 (s, 2 H), 8.78 (s, 2 H) 13C NMR (100 MHz, DMSO-d6): δ 23.4, 43.6, 44.2, 45.9, 48.6, 50, 50.6, 117.3 (q, JC-F 298.0, TFA) 122.8, 123.8, 124, 126.7, 127.2, 128.2, 128.4, 128.5, 129.1, 133, 133.6, 147, 158.8 (q, JC-F 31.5, TFA). LRMS (ESI+): m/z 643.1 (free base [M+H]+, 100%). HRMS (ESI+): m/z Calcd. for C38H47N10+ free base[M+H]+ 643.3980, found 643.3981. FTIR (ATR) νmax/cm-1: 3055, 2961, 2848, 1674, 1461, 1431, 1199, 1179, 1128, 1073, 828, 799, 755, 720, 477. Anal.: Calcd. for C38H46N10·2.5CF3CO2H C 55.66, H 5.27, N 15.10; found C 55.80, H 5.12, N 14.88. 1,8-bis(2-(4-benzyl-1H-1,2,3-triazol-1-yl)ethyl)-1,4,8,11-tetraazacyclotetradecane

(9e).

Similar to the procedure for 9a, 8e (141 mg, 0.183 mmol) in 1,4-dioxane (2 mL) was added HCl



in dioxane (4.0 M, 0.10 mL, 8 equiv.) and stirred for 16 h at rt. The residue was concentrated under reduced pressure and washed with EtOAc to yield 9e·4(HCl)·2.5H2O as a white solid (122 mg, 98%). m.p.: 189 ºC (decomp.). 1H NMR (400 MHz, D2O): δ 1.58 – 1.68 (m, 4 H), 2.26 (t, J 7.0, 4 H), 2.47 – 2.58 (m, 8 H), 2.78 – 2.87 (m, 4 H), 2.97 (t, J 5.5, 4 H), 4.08 (s, 4 H), 4.52 (t, J 5.5, 4 H), 7.27 – 7.46 (m, 10 H), 8.01 (s, 2 H).

13

C NMR (100 MHz, D2O): δ 23.7, 31.4,

43.3, 44.1, 48.2, 48.3, 50.4, 51.1, 124.9, 127.6, 129.4, 129.7, 139.6, 148.5. LRMS (ESI+): m/z 571.3 (free base [M+H]+, 100%). HRMS (ESI+): m/z Calcd. for C32H47N10+ free base [M+H]+ 571.3980, found 571.3979. FTIR (ATR) νmax/cm-1: 3355, 2998, 2365, 1494, 1452, 1225, 1076, 1053, 1028, 968, 729, 699, 583, 463. Anal.: Calcd. for C32H46N10·4HCl·2.5H2O C 50.46, H 7.28, N 18.29; found C 50.53, H 7.43, N 17.79. 1,4,8,11-Tetraazatricyclo[9.3.1.14,8]hexadecane (10). To a solution of cyclam (5.00 g, 25.0 mmol, 1 equiv.) in deionised H2O (300 mL, 0.08 M) (requires heating and/or sonication to dissolve) was added formaldehyde (~37% in H2O, 4.50 mL, 55.0 mmol, 2.2 equiv.) dropwise at 0 °C, the reaction mixture was allowed to warm to rt, and was stirred for 5 h resulting in a white suspension. The precipitate was collected by vacuum filtration, washed with H2O (3 × 50 mL) and dried under high vacuum to yield 10 as a white solid (4.98 g, 89%, typically yields vary from 70-90% over 5-18 h). m.p. 107 – 110 °C (lit.15,31 106 – 108 °C). 1H NMR (200 MHz, CDCl3): δ 1.18 (d, J 13.0, 2 H), 2.13 – 2.34 (m, 2 H), 2.34 – 2.50 (m, 4 H), 2.63 (td, J 12.0, 3.0, 4 H), 2.78 – 2.84 (m, 4 H), 2.91 (d, J 11.0, 2 H), 3.04 – 3.25 (m, 4 H), 5.44 (d, J 11.0, 2 H). LRMS (ESI+) m/z 225.16 ([M + H]+, 100%). Spectroscopic properties matched those previously described.15,31 1-(3-Bromoprop-1-yn-1-yl)naphthalene (11). Using a 2-step procedure 3-(naphthalen-1yl)prop-2-yn-1-ol was prepared and converted to the bromide based on literature procedure.32 Under an argon atmosphere, to a flask charged with 1-iodonaphthalene (5.08 g, 20 mmol, 1


Page 34 of 64

Page 35 of 64 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


equiv.) in THF (40 mL) was added Pd(PPh3)2Cl2 (0.24 g, 5 mol%), CuI (0.12 g, 10 mol%) and DIPEA (6.0 mL, 39.0 mmol, 3.72 equiv.) followed by the addition of propargyl alcohol (4 mL, 65.6 mmol, 3.3 equiv.). The reaction mixture stirred at rt for 2.5 h. The reaction mixture was diluted with saturated ammonium chloride solution (20 mL) and extracted with EtOAc (3 × 100 mL). The combined organic layers were dried over Na2SO4 and loaded onto silica for purification. The compound was purified by automated column chromatography (0 – 20% MeOH/DCM, 10 CV) to yield 3-(naphthalen-1-yl)prop-2-yn-1-ol as a yellow oil (2.41 g, 13.2 mmol, 66%). 1H NMR (300 MHz, CDCl3): δ 4.67 (s, 2 H), 7.43 (t, J 8.0, 1 H), 7.49 – 7.63 (m, 2 H), 7.69 (d, J 7.0, 1 H), 7.80 – 7.87 (m, 2 H), 8.35 (d, J 8.0, 1 H). 13C NMR (75 MHz, CDCl3): δ 51.8, 83.8, 92.1, 120.2, 125.1, 126.0, 126.4, 126.8, 128.2, 129.0, 130.6, 133.1, 133.2. Spectroscopic properties matched those previously described.32 Based upon a general Appel procedure33 3-(Naphthalen-1-yl)prop-2-yn-1-ol (1000 mg, 5.49 mmol, 1 equiv.) was dissolved in DCM (16 mL, 0.33M) in an ice bath, and triphenylphosphine (1.1 equiv., 6.04 mmol, 1.58 g) followed by CBr4 (1.1 equiv., 6.04 mmol, 2.00 g) were added and stirred for 20 mins before concentrating the reaction mixture. The crude reaction mixture was purified by automated column chromatography (100% petroleum ether) to yield 11 as a yellow oil (2.55 g, 49% purity by 1H NMR using duroquinone as an internal standard, 5.34 mmol, 97% yield by 1H NMR, mass impurities may be CBr4). 1H NMR (300 MHz, CDCl3): δ 4.33 (s, 2 H), 7.43 (t, J 8.0, 1 H), 7.50 – 7.64 (m, 2 H), 7.69 (d, J 7.0, 1 H), 7.86 (d, J 8.0, 2 H), 8.31 (d, J 8.0, 1 H) 13C NMR (75 MHz, CDCl3): δ 15.5, 85.1, 89.1, 119.8, 125.2, 126.0, 126.6, 127.1, 128.4, 129.4, 131.0, 133.1, 133.4. Spectroscopic properties matched those previously described.34 1,8-Bis(3-(naphthalen-1-yl)prop-2-yn-1-yl)-1,4,8,11-tetraazacyclotetradecane (12). To 10 (250 mg, 1.1 mmol, 1 equiv.) in MeCN (12 mL, 0.1 M) was added 11 (1.34 g, 49% purity, 2.68



mmol, 2.4 equiv.) and MeCN (12 mL, 0.1 M) and stirred overnight at rt, to yield a white suspension. The reaction mixture was concentrated, and diluted with 2.5 M aqueous NaOH (25 mL), DCM (50 mL) and shaken vigorously; after a biphasic solution formed the organic layer was dried over Na2SO4 and concentrated by rotary evaporation to give a crude brown oil (389 mg). A portion of the crude material (259 mg) was purified by automated reverse phase chromatography (0 – 100% H2O-MeCN (with 0.1% TFA), over 10 CV) MeCN was removed by rotary evaporation and the aqueous phase taken to pH 14 with aqueous NaOH (2.5 M) solution and extracted with DCM (3 × 30 mL). The combined organic layers were dried over Na2SO4 and concentrated to yield 12 as a brown oil (168 mg, 0.32 mmol, 29%, 43% yield based on 2/3rd purified). 1H NMR (300 MHz, CDCl3): δ 1.80 – 1.93 (m, 4 H), 2.68 – 2.98 (m, 16 H), 3.82 – 3.81 – 3.94 (br. m, 4 H), 7.35 – 7.45 (m, 2 H), 7.45 – 7.59 (m, 4 H), 7.63 – 7.69 (m, 2 H), 7.77 – 7.88 (m, 4 H), 8.35 (d, J 8.0, 2 H). 13C NMR (300 MHz, CDCl3): sample decomposed. LRMS (ESI+): m/z not found. FTIR (ATR) νmax/cm-1 2938, 2841, 2199, 1654. 1,8-Bis(3-(naphthalen-1-yl)propyl)-1,4,8,11-tetraazacyclotetradecane (13). To 12 (111 mg, 0.21 mmol, 1 equiv.) in MeOH (10 mL, 0.02M) was backfilled with N2 (× 3) and Pd(C) (1g, 10wt%, 100 mol%) was added and the reaction mixture backfilled with N2 (× 3) followed by bubbling of H2 through the solution using a long needle overnight. the reaction mixture was filtered through celite (eluting with MeOH) and concentrated and purified by automated reverse phase chromatography (0 – 100% H2O-MeCN (with 0.1% TFA), over 10 CV). MeCN was removed by rotary evaporation and the aqueous phase taken to pH 14 using 2.5 M aqueous NaOH solution and extracted with DCM (3 × 30 mL). The combined organic layers were dried over Na2SO4 and concentrated to yield 13 as a yellow waxy solid (28 mg, 0.522 mmol, 25%, >95% by HPLC). 1H NMR (300 MHz, CDCl3): δ 1.64 – 1.77 (m, 4 H), 1.77 – 1.89 (m, 4 H),


Page 36 of 64

Page 37 of 64 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


2.43 – 2.56 (m, 12 H), 2.59 – 2.67 (br. m., 4 H), 2.66 – 2.78 (m, 8 H), 7.19 (d, J 7.0, 2 H), 7.31 (t, J 7.5, 2 H), 7.39 – 7.52 (m, 4 H), 7.63 (d, J 8.0, 2 H), 7.76 – 7.82 (m, 2 H), 7.90 (d, J 8.0, 2 H) 13

C NMR (126 MHz, CDCl3): δ 22.6, 25.7, 26.3, 29.7, 30.7, 50.8, 53.1, 54.3, 123.8, 125.4,

125.5, 125.7, 126.5, 127.9, 128.7, 131.8, 133.8, 138.3. LRMS (ESI+): m/z 559.38 ([M+Na]+, 100%). HRMS (ESI+): m/z Calcd. for C36H49N4+ 537.3957, found 537.3952. FTIR (ATR) νmax/cm-1: 2914, 2872, 1683, 1610. Fe(ClO4)2

complex

of

6,6'-(((1,4,8,11-tetraazacyclotetradecane-1,8-

diyl)bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))bis(2-ethyl-1H-benzo[de]isoquinoline1,3(2H)-dione) (14c). To a solution of 1 (200 mg, 248 µmol, 1.00 equiv.) in EtOH (0.1 M, 2.5 mL) and Fe(ClO4)2.H2O (67.6 mg, 248 µmol, 1.00 equiv.) in EtOH (0.1 M, 2.5 mL) at rt and the reaction mixture heated at reflux for 24 h. The reaction mixture was cooled in an ice bath and the precipitate collected by vacuum filtration. The precipitate was washed with ice-cold ethanol (3 × 2 mL) and diethyl ether (3 × 2 mL) and dried under high vacuum to yield 14c as a purple solid (146 mg, 55%). m.p. 203 °C. UV-Vis (CH3CN) λmax/nm 344, ε 44249. FS (CH3CN) λex/nm 344, λem/nm 345, 419. 1H NMR (300 MHz, DMSO-d6): δ 1.02 – 1.39 (m, 6 H), 1.73 – 2.15 (m, 4 H), 2.64 – 3.05 (m, 8 H), 3.75 – 4.24 (m, 8 H) 7.78 – 8.29 (br. m, 6 H), 8.30 – 9.14 (br. m, 6 H) (8 × H missing or overlapping).

13

C NMR (126 MHz, DMSO-d6): δ 13.1, 30.7, 35.1, 46.6, 123.1,

123.9, 124.6, 126.1, 127.4, 128.8, 129.3, 129.6, 130.9, 132.0, 138.0, 162.9, 163.4 (5 × C missing or overlapping). LRMS (ESI+) m/z 432.16 [M – 2ClO4]2+, 809.45 ([C44H48N12O4 + H]+, 909.50 ([C44H48ClN12O8] – [2H]+). Anal.: Calculated for C44H48Cl2FeN12O12·H2O: C 48.86 H 4.66 N 15.54; Found: C 49.22 H 4.60 N 15.22. FTIR (ATR) νmax/cm-1 1702, 1660, 1590, 1342, 1245, 1085, 785, 755, 623.



Fe(ClO4)3

complex

of

Page 38 of 64


diyl)bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))bis(2-ethyl-1H-benzo[de]isoquinoline1,3(2H)-dione) (14d). Similar to the procedure for 14c, 1 (200 mg, 248 µmol, 1.00 equiv.) in EtOH (0.1 M, 2.5 mL) and Fe(ClO4)3.H2O (92.0 mg, 248 µmol, 1.00 equiv.) in EtOH (0.1 M, 2.5 mL) were refluxed for 24 h then collected and washed to yield 14d·H2O as a golden yellow solid (189 mg, 66%). m.p. 213 °C. UV-Vis (CH3CN) λmax/nm 344, ε 30428. FS (CH3CN) λex/nm 344, λem/nm 345, 419. 1H NMR (300 MHz, DMSO-d6): δ 1.25 (t, J 7.0, 6 H), 1.95 – 2.11 (m, 4 H), 2.69 – 2.89 (m, 8 H), 4.02 – 4.17 (m, 8 H), 7.94 (t, J 8.0, 2 H), 8.05 (d, J 8.0, 2 H), 8.17 (d, J 8.5, 2 H), 8.33 – 8.70 (br. m, 4 H), 8.89 (s, 2 H) (8 × H missing or overlapping).

13

C NMR (126

MHz, DMSO-d6): δ 13.5, 22.6, 35.6, 44.2, 44.9, 46.9, 49.6, 52.1, 123.1, 123.9, 124.7, 126.2, 127.6, 128.8, 129.2, 129.6, 130.9, 132.0, 138.0, 142.4, 162.9, 163.4. LRMS (APCI) m/z 809.36 ([C44H48N12O4]

+

H)+,

909.42

([C44H48ClN12O8] – [2H]+).

Anal.:

Calculated

for

C44H48Cl3FeN12O16·H2O: C 48.06 H 4.77 N 15.28; Found: C 48.40 H 4.80 N 15.26. FTIR (ATR) νmax/cm-1 1670, 1657, 1591, 1341, 1245, 1067, 791, 756, 623. Sm(ClO4)3

complex

of


diyl)bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))bis(2-ethyl-1H-benzo[de]isoquinoline1,3(2H)-dione) (14e). Similar to the procedure for 14c, 1 (200 mg, 248 µmol, 1.00 equiv.) in EtOH (0.1 M, 2.5 mL) and Sm(ClO4)3 (278 mg, 248 µmol, 1.00 equiv.) in EtOH (0.1 M, 2.5 mL) were refluxed for 24 h then collected and washed to yield 14e·H2O as a light yellow solid (243 mg, 78%). m.p. 290 – 293 °C. UV-Vis (CH3CN) λmax/nm 344, ε 45175. FS (CH3CN) λex/nm 344, λem/nm 345, 420. 1H NMR (300 MHz, DMSO-d6): δ 1.22 (t, J 7.0, 6 H), 1.73 – 1.85 (m, 4 H), 2.53 – 2.60 (m, 4 H), 2.65 – 2.72 (m, 4 H), 2.78 – 2.85 (m, 4 H), 2.89 – 2.96 (m, 4 H), 3.76 (s, 4 H), 4.09 (q, J 7.0, 4 H), 7.89 (t, J 8.0, 2 H), 7.97 (d, J 8.0, 2 H), 8.07 (d, J 8.5, 2 H), 8.53 –


Page 39 of 64 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


8.59 (m, 4 H), 8.69 (s, 2 H).

13

C NMR (126 MHz, DMSO-d6): δ 13.5, 24.6, 35.5, 46.7, 47.4,

48.0, 48.8, 50.9, 122.3, 123.6, 124.4, 126.0, 127.0, 128.6, 129.1, 129.5, 130.8, 131.8, 138.0, 144.1, 162.8, 163.3. LRMS (APCI) No molecular ion or fragments observed. Anal.: Calculated for C44H48Cl3SmN12O16·H2O: C 41.43 H 3.95 N 13.18; Found: C 41.36 H 4.33 N 12.87. FTIR (ATR) νmax/cm-1 1702, 1658, 1591, 1341, 1246, 1066, 790, 756, 623. Co(ClO4)2

complex

of


diyl)bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))bis(2-ethyl-1H-benzo[de]isoquinoline1,3(2H)-dione) (14f). Similar to the procedure for 14c, 1 (200 mg, 248 µmol, 1.00 equiv.) in EtOH (0.1 M, 2.5 mL) and Co(ClO4)2.6H2O (90.4 mg, 248 µmol, 1.00 equiv.) in EtOH (0.1 M, 2.5 mL) were refluxed for 24 h then collected and washed to yield 16f·H2O as a beige solid (189.9 mg, 72%). m.p. 250 – 255 °C. UV-Vis (CH3CN) λmax/nm 335, ε 21044. 1H NMR (300 MHz, DMSO-d6): δ 1.26 (m, 8 H), 2.13 – 2.30 (m, 4 H), 2.70 – 3.06 (m, 16 H), 4.15 (m, 4 H), 7.98 – 8.17 (m, 2 H), 8.23 – 8.48 (m, 4 H), 8.68 – 8.88 (m, 4 H), 9.38 (s, 2 H), (4 × H peaks missing or overlapping).

13

C NMR (126 MHz, DMSO-d6): δ 13.5, 35.7, 47.4, 123.5, 125.7,

126.4, 127.6, 128.8, 129.9, 130.8, 132.5, 136.8, 162.9, 163.3 (8 × C peaks missing or overlapping). LRMS (APCI) m/z 809.43 ([C44H48N12O12] + H)+, 433.15 (M – 2ClO4)2+, 405.20 ([C44H48N12O12]

+ 2

H)2+,

289.09

(M

+ H –

2ClO4)3+

Anal.: Calculated

for

C44H48Cl2CoN12O12·H2O: C 44.98 H 5.15 N 14.31; Found: C 44.69 H 4.66 N 14.34. FTIR (ATR) νmax/cm-1 1702, 1659, 1590, 1341, 1245, 1083, 784, 622. Mn(II)

complex

of


diyl)bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))bis(2-ethyl-1H-benzo[de]isoquinoline1,3(2H)-dione) (14g). Similar to the procedure for 14c, 1 (200 mg, 248 µmol, 1.00 equiv.) in EtOH (0.01 M, 2.5 mL) and Mn(ClO4)2.6H2O (89.4 mg, 248 µmol, 1.00 equiv.) in EtOH (0.01



M, 2.5 mL) were refluxed for 24 h then collected and washed to yield 14g·5H2O as a brown solid (102.0 mg, 39%). m.p. 289-295 °C. UV-Vis (CH3CN) λmax/nm 343, ε 28270. 1H NMR (300 MHz, DMSO-d6): δ 1.22 (t, J 6.5, 6 H), 1.72 – 1.81 (m, 4 H), 2.25 – 2.30 (m, 4 H), 2.62 – 2.69 (m, 4 H), 2.71 – 2.80 (m, 4 H), 3.76 (s, 4 H), 4.03 – 4.15 (m, 4 H), 7.86 – 7.93 (m, 2 H), 7.97 (d, J 7.5, 2 H), 8.08 (d, J 7.5, 2 H), 8.53 – 8.59 (m, 4 H), 8.67 (s, 2 H), (2 × H peaks missing or overlapping). 13C NMR (126 MHz, DMSO-d6): δ 13.5, 24.6, 35.5, 46.7, 47.4, 48.0, 48.8, 50.9, 123.0, 123.7, 124.4, 126.1, 127.0, 128.6, 129.2, 129.4, 130.7, 131.8, 138.0, 144.0, 162.8, 163.3. LRMS (APCI) m/z 431.67 (M – 2ClO4)2+ Anal.: Calculated for C44H48Cl2MnN12O12·3H2O: C 47.32 H 4.87 N 15.05; Found: C 47.33 H 4.47 N 15.12. FTIR (ATR) νmax/cm-1 1702, 1659, 1590, 1341, 1245, 1090, 782, 755, 622. Zn(ClO4)2 complex of 1,8-bis((1-(naphthalen-1-yl)-1H-1,2,3-triazol-4-yl)methyl)-1,4,8,11tetraazacyclotetradecane (15a). Similar to the procedure for 14c, 5d (82 mg, 0.133 mmol, 1.0 equiv.) and Zn(ClO4)2·6H2O (49 mg, 0.133 mmol, 1.0 equiv.) in EtOH (3 mM, 43 mL) were refluxed for 2 h then collected and washed and azeotroped with toluene to yield 15a·0.1Zn(ClO4)2·0.75C7H8 as a beige solid (34 mg, 28%). m.p. 241 – 290 °C (decomp.). 1H NMR (200 MHz, DMSO-d6): δ 1.99 – 2.12 (m, 4 H), 2.61 – 2.97 (br. m, 8 H), 2.97 – 3.15 (br. m, 4 H), 3.64 – 3.82 (br. m, 4 H), 6.90 – 7.10 (br. m, 2 H), 7.48 – 7.85 (m, 10 H), 8.07 - 8.36 (m, 4 H), 8.55 – 8.65 (br. m, 0.6 H), 8.70 (s, 0.3 H), 8.87 (s, 0.6 H), 8.90 (s, 0.2 H), 8.92 (s, 0.1 H), 9.02 (s, 0.1 H), 9.09 (s, 0.1 H). LRMS (ESI+): m/z 340.17 [5d+Zn]2+, 615.38 [5d+H]+; Anal.: Calculated for C36H42Cl2N10O8Zn·0.10 Zn(ClO4)2·0.75 C7H8 C 50.88, H 4.88, N 14.38 Result C 51.22 H 4.54 N 14.07. Cu(ClO4)2 complex of 1,8-bis((1-(naphthalen-1-yl)-1H-1,2,3-triazol-4-yl)methyl)-1,4,8,11tetraazacyclotetradecane (15b). Similar to the procedure for 14c, 5d (81 mg, 0.132 mmol, 1.0


Page 40 of 64

Page 41 of 64 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


equiv.) and Cu(ClO4)2·6H2O (49 mg, 0.133 mmol, 1.0 equiv.) in EtOH (3 mM, 43 mL) were refluxed for 2 h then collected and washed to yield 15b·0.11Cu(ClO4)2 as a blue powder (62 mg, 52%). m.p. 253 – 280 °C (decomp.). LRMS (ESI+) m/z 338.67 [5d+Cu]2+, 776.24 [5d+Cu+ClO4]+; Anal.: Calculated for C36H42Cl2N10O8Cu·0.11 Cu(ClO4)2 C 47.72, H 4.67, N 15.46. Found C 47.79 H 4.49 N 15.33. Zn(ClO4)2 complex of 1,8-bis(2-(4-(naphthalen-1-yl)-1H-1,2,3-triazol-1-yl)ethyl)-1,4,8,11tetraazacyclotetradecane (16a). To a solution of 9a·3(HCl) (37 mg, 0.050 mmol) in EtOH (2 mL) was added an excess of Ambersep® 900 resin (hydroxide form, pre-swelled with H2O for 30 min and EtOH for 30 min) in EtOH (10 mL). The mixture was stirred for 15 min and filtered. To the filtrate was added a solution of Zn(ClO4)2·6H2O (20 mg, 0.054 mmol) in EtOH (1 mL). The reaction mixture was stirred at temperature rt for 16 h. The reaction mixture was centrifuged and the precipitate was washed with ice-cold EtOH and Et2O, dried under high vacuum and lyophilised to yield 16a·H2O as an off-white solid (32 mg, 72%). m.p.: 188 ºC (decomp.). LRMS (ESI+): m/z 353.1 ([M-2ClO4]2+, 100%), 805.1 ([M-ClO4]+, 37%). HRMS (ESI+): m/z Calcd. for C38H46ClN10O4Zn+ [M-ClO4]+ 805.2678, found 805.2681. FTIR (ATR) νmax/cm-1: 1455, 1339, 1259, 1214, 1090, 948, 930, 885, 804, 779, 736, 622, 435. Anal.: Calcd. for C38H46Cl2N10O8Zn·H2O C 49.33, H 5.23, N 15.14; found C 49.48, H 5.09, N 15.08. Cu(ClO4)2 complex of 1,8-bis(2-(4-(naphthalen-1-yl)-1H-1,2,3-triazol-1-yl)ethyl)-1,4,8,11tetraazacyclotetradecane (16b). Similar to the procedure to 16a, 9a·3(HCl) (24 mg, 0.032 mmol), Cu(ClO4)2·6H2O (13 mg, 0.035 mmol) and stirred at rt for 16 h to yield 16b as a black solid (23 mg, 80%). m.p.: 182 ºC (decomp.). LRMS (ESI+): m/z 352.5 ([M-2ClO4]2+, 100%), 803.9 ([M-ClO4]+, 23%). HRMS (ESI+): m/z Calcd. for C38H46ClCuN10O4+ [M-2ClO4]2+ 352.6596, found 352.6598. FTIR (ATR) νmax/cm-1: 1462, 1427, 1352, 1085, 946, 880, 803, 778,



Page 42 of 64

740, 671, 622, 565, 433. Anal.: Calcd. for C38H46Cl2CuN10O8 C 50.42, H 5.12, N 15.47; found C 50.40, H 5.40, N 15.30. Cu(ClO4)2 complex of 6,6'-(1,1'-((1,4,8,11-tetraazacyclotetradecane-1,8-diyl)bis(ethane2,1-diyl))bis(1H-1,2,3-triazole-4,1-diyl))bis(2-ethyl-1H-benzo[de]isoquinoline-1,3(2H)dione) (17b) (Compound 9b as a TFA salt and its Zn complex (17a) have been reported previously).15c Similar to the procedure for 17a, 9b·3TFA (41 mg, 0.036 mmol) was complexed with Cu(ClO4)2·6H2O (13 mg, 0.035 mmol) at reflux for 16 h to yield 17b·2H2O as a brown solid (29 mg, 74%). m.p.: 263 ºC (decomp.). LRMS (ESI+): m/z 449.5 ([M-2ClO4]2+, 100%), 997.9 ([M+ClO4]+, 16%). HRMS (ESI+): m/z Calcd. for C46H52ClCuN12O8+ [M-ClO4]+ 998.3010, found 998.3020. FTIR (ATR) νmax/cm-1: 1694, 1650, 1613, 1587, 1447, 1385, 1371, 1341,

1244,

1062,

952,

930,

894,

872,

841,

784,

758,

622.

Anal.:

Calcd.

C46H52Cl2CuN12O12·2H2O C 48.66, H 4.97, N 14.80; found C 48.68, H 4.93, N 14.62. Zn(ClO4)2 complex of 1,8-bis(2-(4-(naphthalen-2-yl)-1H-1,2,3-triazol-1-yl)ethyl)-1,4,8,11tetraazacyclotetradecane (18a). Similar to the procedure for 16a, 9c·2.5TFA (33 mg, 0.037 mmol) was complexed with Zn(ClO4)2·6H2O (14 mg, 0.038 mmol) at rt for 16 h to yield 18a as an off-white solid (27 mg, 87%). m.p.: 252 ºC (decomp.). LRMS (ESI+): m/z 353.1 ([M2ClO4]2+, 100%), 804.9 ([M-ClO4]+, 8%). HRMS (ESI+): m/z Calcd. for C38H46ClN10O4Zn+ [MClO4]+ 805.2678, found 805.2684. FTIR (ATR) νmax/cm-1: 1454, 1335, 1238, 1075, 1057, 1013, 994, 972, 938, 930, 907, 886, 873, 842, 819, 764, 738, 623, 482. Anal.: Calcd. C38H46Cl2N10O8Zn C 50.31, H 5.11, N 15.44; found C 50.5, H 5.11, N 15.15. Cu(ClO4)2 complex of 1,8-bis(2-(4-(naphthalen-2-yl)-1H-1,2,3-triazol-1-yl)ethyl)-1,4,8,11tetraazacyclotetradecane (18b). Similar to the procedure for 16a, 9c·2.5TFA (33 mg, 0.037 mmol) was complexed with Cu(ClO4)2·6H2O (14 mg, 0.037 mmol) at rt for 16 h to yield


Page 43 of 64 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


18b·H2O as a purple solid (28 mg, 90%). m.p.: 191 ºC (decomp.). LRMS (ESI+): m/z 352.5 ([M-2ClO4]2+,

100%),

804.0

([M+ClO4]+,

4%).

HRMS

(ESI+):

m/z

Calcd.

for

C38H46ClCuN10O4+ [M-ClO4]+ 804.2683, found 804.2680. FTIR (ATR) νmax/cm-1: 1458, 1433, 1231, 1088, 995, 938, 905, 866, 844, 819, 753, 622, 477. Anal.: Calcd. C38H46Cl2CuN10O8·H2O C 49.43, H 5.24, N 15.17; found C 49.67, H 5.18, N 15.20. Cu(ClO4)2

complex

of

1,8-bis(2-(4-phenyl-1H-1,2,3-triazol-1-yl)ethyl)-1,4,8,11-

tetraazacyclotetradecane (19b) (Compound 9d as a TFA salt and Zn complex (19a) has been reported previously).15c Similar to the procedure for 16a, 9d·3TFA (25 mg, 0.028 mmol) was complexed with Cu(ClO4)2·6H2O (9.4 mg, 0.025 mmol) at reflux for 16 h to yield 19b·H2O as a purple solid (32.2 mg, 71%). m.p.: 186 – 189 ºC HRMS (ESI+): m/z Calcd. for C30H42ClCuN10O4+ [M-ClO4]+ 704.2370, found 704.2365. FTIR (ATR) νmax/cm-1: 1467, 1072, 976, 929, 828, 769, 738, 697, 622, 513. Anal.: Calcd. for C30H42Cl2CuN10O8·H2O C 43.77, H 5.39, N 17.02; found C 43.58, H 5.24, N 16.89. Zn(ClO4)2

complex

of


tetraazacyclotetradecane (20a). Similar to the procedure for 16a, 9e·3(HCl) (40 mg, 0.059 mmol) was complexed with Zn(ClO4)2·6H2O (24 mg, 0.064 mmol) at rt for 16 h to yield 20a as a white solid (42 mg, 86%). m.p.: 129 – 132 ºC. LRMS (ESI+): m/z 317.1 ([M-2ClO4]2+, 100%), 733.0 ([M-ClO4]+, 23%). HRMS (ESI+): m/z Calcd. for C32H46ClN10O4Zn+ [M-ClO4]+ 733.2678, found 733.2677. FTIR (ATR) νmax/cm-1: 3261, 2873, 1495, 1454, 1331, 1228, 1071, 1030, 974, 930, 906, 886, 838, 809, 729, 700, 621, 464. Anal.: Calcd. for C32H46Cl2N10O8Zn C 46.03, H 5.55, N 16.77; found C 45.91, H 5.43, N 16.63. Cu(ClO4)2

complex

of


tetraazacyclotetradecane (20b) Similar to the procedure for 16a, 9e·3(HCl) (40 mg, 0.059



mmol) was complexed with Cu(ClO4)2·6H2O (24 mg, 0.065 mmol) at rt for 16 h to yield 20b as a vibrant purple solid (27 mg, 55%). m.p.: 146 – 148 ºC LRMS (ESI+): m/z 316.5 ([M-2ClO4]2+, 100%), 732.1 ([M-ClO4]+, 16%). HRMS (ESI+): m/z Calcd. for C32H46ClCuN10O4+ [M-ClO4]+ 732.2683, found 732.2680. FTIR (ATR) νmax/cm-1: 1495, 1454, 1428, 1070, 1029, 929, 834, 730, 699, 621, 463. Anal.: Calcd. for C32H46Cl2CuN10O8 C 45.15, H 5.68, N 16.45; found C 45.15, H 5.61, N 16.38. Zn(ClO4)2

complex

of


diyl)bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))bis(2-(3-hydroxypropyl)-1Hbenzo[de]isoquinoline-1,3(2H)-dione) (21a). 5i (38.5 mg, 0.045 mmol, 1.0 equiv.) was dissolved in EtOH (1.4 mL), was heated to reflux, and Zn(ClO4)2 (17.8 mg, 0.048 mmol, 1.0 equiv.) in Et2O (0.46 mL) was added and heated at reflux for 24 h. The solution was allowed to cool to rt and the precipitate collected by vacuum filtration and washed with EtOH (3 × 3 mL) and dissolved in MeCN/H2O (5 mL) and filtered then freeze-dried to yield a yellow fluffy solid (35 mg, 0.031 mmol, 69%). 1H NMR (300 MHz, D2O) δ 1.82 – 1.94 (m, 4 H) 2.09 – 2.22 (m, 4 H) 2.85 – 3.00 (m, 4 H) 3.05 – 3.16 (m, 4 H) 3.43 – 3.52 (m, 4 H) 3.64 – 3.73 (m, 4 H) 3.96 – 4.04 (m, 4 H) 4.05 – 4.16 (m, 4 H) 7.22 – 7.32 (m, 2 H) 7.59 – 7.68 (m, 4 H) 8.05 – 8.14 (m, 2 H) 8.21 – 8.28 (m, 2 H) 8.29 – 8.33 (m, 2 H) (8 × H missing or overlapping) . Anal.: Calcd. For C46Cl2H52N12O14Zn·0.45H2O C 48.64, H 4.64, N 14.80; found C 49.00, H 5.02, N 14.60. ZnCl2

complex

of


diyl)bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))bis(2-(3-hydroxypropyl)-1Hbenzo[de]isoquinoline-1,3(2H)-dione) (21b). 5i (1000 mg, 1.15 mmol, 1.0 equiv.) in H2O (milliQ, 70 mL) was heated to reflux, and ZnCl2 (1.0 M in diethyl ether stock solution, 1.15 mmol, 1.0 equiv.) was added and refluxed for 2 h. The solution was cooled to rt and concentrated


Page 44 of 64

Page 45 of 64 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


under reduced pressure (to

Antitubercular Bis-Substituted Cyclam Derivatives: StructureâActivity

Recommend Documents

Antitubercular Bis-Substituted Cyclam Derivatives: StructureâActivity